In clinical practice, reducing the burden of persistent atrial fibrillation by pharmacological means is challenging. We explored if blocking the background and the acetylcholine-activated inward rectifier potassium currents (I K1 and I KACh) could be antiarrhythmic in persistent atrial fibrillation. We thus tested the hypothesis that blocking I K1 and I KACh with chloroquine decreases the burden of persistent atrial fibrillation. We used patch clamp to determine the IC 50 of I K1 and I KACh block by chloroquine and molecular modeling to simulate the interaction between chloroquine and Kir2.1 and Kir3.1, the molecular correlates of I K1 and I KACh. We then tested, as a proof of concept, if oral chloroquine administration to a patient with persistent atrial fibrillation can decrease the arrhythmia burden. We also simulated the effects of chloroquine in a 3D model of human atria with persistent atrial fibrillation. In patch clamp the IC 50 of I K1 block by chloroquine was similar to that of I KACh. A 14-day regimen of oral chloroquine significantly decreased the burden of persistent atrial fibrillation in a patient. Mathematical simulations of persistent atrial fibrillation in a 3D model of human atria suggested that chloroquine prolonged the action potential duration, leading to failure of reentrant excitation, and the subsequent termination of the arrhythmia. The combined block of I K1 and I KACh can be a targeted therapeutic strategy for persistent atrial fibrillation.